Logo image of NTBL

NOTABLE LABS LTD (NTBL) Stock Fundamental Analysis

NASDAQ:NTBL - Nasdaq - IL0012002452 - Common Stock - Currency: USD

0.2479  -0.09 (-27.68%)

After market: 0.2456 0 (-0.93%)

Fundamental Rating

1

Overall NTBL gets a fundamental rating of 1 out of 10. We evaluated NTBL against 559 industry peers in the Biotechnology industry. Both the profitability and financial health of NTBL have multiple concerns. NTBL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NTBL had negative earnings in the past year.
NTBL had a negative operating cash flow in the past year.
NTBL had negative earnings in each of the past 5 years.
NTBL had a negative operating cash flow in each of the past 5 years.
NTBL Yearly Net Income VS EBIT VS OCF VS FCFNTBL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of NTBL (-152.09%) is worse than 86.15% of its industry peers.
NTBL's Return On Equity of -232.90% is on the low side compared to the rest of the industry. NTBL is outperformed by 71.23% of its industry peers.
Industry RankSector Rank
ROA -152.09%
ROE -232.9%
ROIC N/A
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
NTBL Yearly ROA, ROE, ROICNTBL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

NTBL has a better Gross Margin (37.70%) than 76.91% of its industry peers.
NTBL's Gross Margin has declined in the last couple of years.
NTBL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
NTBL Yearly Profit, Operating, Gross MarginsNTBL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

NTBL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NTBL has more shares outstanding
The number of shares outstanding for NTBL has been increased compared to 5 years ago.
Compared to 1 year ago, NTBL has a worse debt to assets ratio.
NTBL Yearly Shares OutstandingNTBL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
NTBL Yearly Total Debt VS Total AssetsNTBL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

NTBL has an Altman-Z score of -16.80. This is a bad value and indicates that NTBL is not financially healthy and even has some risk of bankruptcy.
NTBL has a Altman-Z score of -16.80. This is amonst the worse of the industry: NTBL underperforms 84.55% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that NTBL is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.03, NTBL perfoms like the industry average, outperforming 41.92% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -16.8
ROIC/WACCN/A
WACC10.75%
NTBL Yearly LT Debt VS Equity VS FCFNTBL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

NTBL has a Current Ratio of 2.77. This indicates that NTBL is financially healthy and has no problem in meeting its short term obligations.
NTBL's Current ratio of 2.77 is on the low side compared to the rest of the industry. NTBL is outperformed by 68.56% of its industry peers.
A Quick Ratio of 2.77 indicates that NTBL has no problem at all paying its short term obligations.
With a Quick ratio value of 2.77, NTBL is not doing good in the industry: 67.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.77
NTBL Yearly Current Assets VS Current LiabilitesNTBL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.56% over the past year.
Looking at the last year, NTBL shows a very negative growth in Revenue. The Revenue has decreased by -34.79% in the last year.
Measured over the past years, NTBL shows a very negative growth in Revenue. The Revenue has been decreasing by -12.08% on average per year.
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -63.21% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NTBL Yearly Revenue VS EstimatesNTBL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
NTBL Yearly EPS VS EstimatesNTBL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTBL. In the last year negative earnings were reported.
Also next year NTBL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTBL Price Earnings VS Forward Price EarningsNTBL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTBL Per share dataNTBL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

NTBL's earnings are expected to decrease with -63.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.21%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTBL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOTABLE LABS LTD

NASDAQ:NTBL (10/22/2024, 8:00:02 PM)

After market: 0.2456 0 (-0.93%)

0.2479

-0.09 (-27.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2024-08-14/amc
Earnings (Next)11-12 2024-11-12/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners16.5%
Ins Owner Change0%
Market Cap2.39M
Analysts80
Price Target9.18 (3603.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.38%
Min EPS beat(2)-25.98%
Max EPS beat(2)-4.77%
EPS beat(4)0
Avg EPS beat(4)-294.73%
Min EPS beat(4)-1133.4%
Max EPS beat(4)-4.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-31.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.65
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-6.91
EYN/A
EPS(NY)-3.63
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0.03
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -152.09%
ROE -232.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.7%
FCFM N/A
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
F-Score1
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.83%
Cap/Sales 25.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.77
Altman-Z -16.8
F-Score1
WACC10.75%
ROIC/WACCN/A
Cap/Depr(3y)72.79%
Cap/Depr(5y)45.66%
Cap/Sales(3y)111.54%
Cap/Sales(5y)70.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.33%
OCF growth 3YN/A
OCF growth 5YN/A